ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NITE Nightstar Therapeutics Plc ADS

25.41
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nightstar Therapeutics Plc ADS NASDAQ:NITE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 25.41 18.50 25.41 0 01:00:00

Knight Capital Group, Inc. Reports Inducement Grants Under NASDAQ Marketplace Rule 5635

04/06/2009 1:00pm

PR Newswire (US)


Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Nightstar Therapeutics Plc ADS Charts.
JERSEY CITY, N.J., June 4 /PRNewswire-FirstCall/ -- Knight Capital Group, Inc. (NASDAQ:NITE) today announced that on June 1, 2009 the Company issued a total of 292,398 shares of restricted shares to three new employees. The Shares were granted as inducements to employment under the Company's 2009 Inducement Award Plan in accordance with NASDAQ Marketplace Rule 5635. The 2009 Inducement Award Plan contains terms similar to that of the Company's 2006 Equity Incentive Plan. The fair value of shares granted was based on the average of the high and low price of Knight common stock on the business day immediately preceding the date of grant. The shares vest ratably over three years on each anniversary of the date of grant. About Knight Knight Capital Group, Inc. (NASDAQ:NITE) is a leading financial services firm that provides electronic and voice access to the global capital markets across multiple asset classes for buy-side, sell-side and corporate clients. In Global Markets, we provide market access and trade execution services in nearly every U.S. equity security and a large number of global equities and fixed income, foreign exchange, futures and options. Our approach to trading combines deep liquidity with robust trading technology and capital facilitation, when necessary, to deliver high quality trade executions consistent with client defined measures. Our Corporate segment invests in strategic, financial services-oriented opportunities, allocates, deploys and monitors all capital and maintains all corporate overhead expenses. Our Asset Management segment is reported as a discontinued operation as of March 31, 2009. More information about Knight can be found at http://www.knight.com/. Certain statements contained herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about the Company's industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict including, without limitation, risks associated with (i) the costs, integration, performance and operation of businesses recently acquired, or that may be acquired in the future, by the Company, and (ii) the closing of the sale of substantially all of the assets of the Asset Management business and costs and expenses associated with the Company's exit from the Asset Management business. Since such statements involve risks and uncertainties, the actual results and performance of the Company may turn out to be materially different from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made herein. Readers should carefully review the risks and uncertainties disclosed in the Company's reports with the U.S. Securities and Exchange Commission (SEC), including, without limitation, those detailed under the headings "Certain Factors Affecting Results of Operations" and "Risk Factors" in the Company's Annual Report on Form 10-K for the year-ended December 31, 2008, and in other reports or documents the Company files with, or furnishes to, the SEC from time to time. This information should also be read in conjunction with the Company's Consolidated Financial Statements and the Notes thereto contained in the Company's Annual Report on Form 10-K for the year-ended December 31, 2008, and in other reports or documents the Company files with, or furnishes to, the SEC from time to time. DATASOURCE: Knight Capital Group, Inc. CONTACT: Margaret Wyrwas, Senior Managing Director, Communications, Marketing & Investor Relations, +1-201-557-6954, , or Kara Fitzsimmons, Director, Media Relations, +1-201-356-1523, , or Jonathan Mairs, Vice President, Corporate Communications, +1-201-356-1529, , all of Knight Capital Group, Inc. Web Site: http://www.knight.com/

Copyright

1 Year Nightstar Therapeutics Plc ADS Chart

1 Year Nightstar Therapeutics Plc ADS Chart

1 Month Nightstar Therapeutics Plc ADS Chart

1 Month Nightstar Therapeutics Plc ADS Chart